Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.709
-$0.0449-5.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.60M | 1.60M | 2.55M | 2.14M | 1.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.28M | 8.46M | 8.13M | 7.92M | 9.62M |
| Operating Income | -6.28M | -8.46M | -8.13M | -7.92M | -9.62M |
| Income Before Tax | -6.25M | -8.37M | -7.85M | -7.43M | -9.36M |
| Income Tax Expenses | 4.70K | -- | 7.40K | 7.40K | -4.60K |
| Earnings from Continuing Operations | -6.26M | -8.37M | -7.86M | -7.43M | -9.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.26M | -8.37M | -7.86M | -7.43M | -9.36M |
| EBIT | -6.28M | -8.46M | -8.13M | -7.92M | -9.62M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.16 | -0.25 | -0.26 | -0.25 | -0.34 |
| Normalized Basic EPS | -0.10 | -0.15 | -0.16 | -0.16 | -0.21 |
| EPS Diluted | -0.16 | -0.25 | -0.26 | -0.25 | -0.34 |
| Normalized Diluted EPS | -0.10 | -0.15 | -0.16 | -0.16 | -0.21 |
| Average Basic Shares Outstanding | 38.32M | 33.80M | 30.56M | 29.89M | 27.23M |
| Average Diluted Shares Outstanding | 38.32M | 33.80M | 30.56M | 29.89M | 27.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |